ClinicalTrials.gg
Status unknownNCT05015023Updated Feb 8, 2023

Effectiveness of Health Education Provided to Couples on Utilization of Maternity Waiting Homes in Rural Ethiopia

An interventional study of Behavioral intervention in Maternal Death and Maternal Behavior, sponsored by Jimma University. Status unknown at 1 site in Ethiopia. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Jimma University · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

Maternity waiting homes (MWHs) were identified as a solution to improve pregnancy outcomes by bringing women living in geographically isolated areas closer to a healthcare facility. Literature shows that MWHs contribute significantly to the reduction of maternal death and stillbirth among users. Despite its importance in improving maternal \& neonatal health outcomes, the utilization of MWHs is very low in Ethiopia. It is important to investigate what strategies could be effective in improving MWH utilization. Therefore, in this study cluster-randomized controlled trials will be conducted to evaluate the effect of male partner involvement intervention on MWH utilization in Ethiopia.

Read the detailed description

The primary cause of adverse maternal health outcomes has been identified to be the delay in reaching care. This is often attributed to the long distances women need to travel to gain access to health facilities. Literature shows that maternity waiting homes contribute significantly to the reduction of maternal death and stillbirth among users. Despite its importance in improving maternal and neonatal health outcomes, the utilization of MWHs is very low in Ethiopia. So, it is important to investigate what strategies could be effective in improving MWH utilization in Ethiopia.

The aim of this study is to evaluate the effect of male partner involvement intervention on MWH utilization in Hadiya Zone, Southern Ethiopia. A cluster-randomized controlled trial will be performed. The intervention will have two arms, i.e., intervention and control. It will be a behavioral intervention. The interventions will be health education, home visit, and the provision of Information Education Communication (IEC) materials/leaflets. Health education will be delivered to "husband-expectant wife" pairs at the baseline. Then home visits will be conducted two times (in the third and fifth months of the intervention period). Leaflets will be provided to the study participants three times, i.e., at the baseline and during every home visit. The study participants will be pregnant women at the beginning of their second trimester living with their male partners at the time of the study.

Randomization will be conducted at the cluster level. Clusters will be Kebeles'. There will be 16 clusters or Kebeles. Data collectors (assessors) will be masked. The trial sample size will be 320 [160 in each arm]. A Generalized Estimating Equations model will be used. Data analysis will be conducted by SPSS or STATA software (as appropriate) using an Intention-To-Treat Approach. The duration of the intervention will be six months.

02

Conditions studied

  • Maternal Death
  • Maternal Behavior

Browse trials for

Keywords

  • maternity waiting home, male partner, Ethiopia
03

In context

Maternal Death

77 studies on the registry are indexed under Maternal Death; 19 are open to participants now.

This study's planned enrollment of 320 is below the median of 1,126 across 57 interventional studies indexed under Maternal Death.

Browse Maternal Death studies →

Lead sponsor

Jimma University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women at the beginning of second trimesters (14-16 weeks of gestation)
  • Pregnant women currently live with their male partners
  • Pregnant women permanent residents of the study area
  • Pregnant women live in a place ≥2 hours of walking distance from the nearest health facility and/or have no access to public transportation
  • Pregnant women whose husbands/male partners will be willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant women ≤ 13 weeks of gestation
  • Pregnant women not living with their male partners at the time of the study
  • Pregnant women who are not permanent residents of the study area
  • Pregnant women live in a place \< 2 hours of walking distance from the nearest health facility or have access to transportation
  • Pregnant women whose husbands are not willing to participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Intervention

    The behavioral intervention will be conducted on the experimental group for consecutive six months. The components of the intervention will be group health education, provision of IEC materials/Leaflets, and home visits.

    Behavioral: Behavioral intervention

  • No intervention
    Control

    The routine care will be continued in the control group.

Interventions

  • BehavioralBehavioral intervention

    A cluster-randomized controlled trial will be conducted.

06

What researchers measure

Primary outcomes

  1. Utilization of MWH

    Utilization of MWH is the use of MWHs by pregnant women in their final weeks of pregnancy to bridge the geographic gap in obstetric care. It is the proportion of pregnant women who use MWHs in the final weeks of pregnancy among the eligible women who are study participants.

    Time frame: up to six months

Secondary outcomes

  1. Level of Maternal Knowledge and Attitude

    Knowledge will be measured using 'Yes' or 'No' questions and attitude will be measured using the Likert scale. There will be 7 questions for the knowledge assessment and 5 questions with 5 points Likert scales for the attitude assessment. Individual scores on each item will be added to yield the sum score. Participants who score above the median in the assessment will be regarded to be knowledgeable or have a good attitude about MWHs, while those who score below the median will be judged to have poor knowledge or an unfavorable attitude.

    Time frame: up to six months

07

Study locations

1 of 1 sites recruiting
  • Jimma University
    Jimma, Oromia 378, Ethiopia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for May 2023, 6 months after the start.

Of 35 interventional studies with no phase under Maternal Death, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 41. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 20, 2021
StartActual
Nov 1, 2022
Primary completionEst.
May 2023
CompletionEst.
Jun 2023
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05015023
Lead sponsor
Jimma University
Responsible party
Teklemariam Yarinbab, MPH (Assistant Professor, Jimma University) — Principal investigator
First posted
Aug 20, 2021
Start date
Nov 1, 2022
Primary completion
May 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Feb 8, 2023

Study contacts

Teklemariam E Yarinbab, MPH
Contact
teklemariam36@gmail.com
+251930504891
Tefera Belachew, PhD
Contact
teferabelachew2@gmail.com
+251917804072
Teklemariam E Yarinbab, MPH
principal investigator · Mizan Tepi University
Hailay A Gesesew, PhD
principal investigator · Torrens University Australia
Tefera Belachew, PhD
principal investigator · Jimma University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion